Aurobindo Pharma Ltd

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd's US FDA-inspected Raleigh Plant in North Carolina has been classified as Voluntary Action Indicated (VAI) after a 17-day inspection from March 24 to April 10, 2025, resulting in 11 observations. The company has received the Establishment Inspection Report (EIR) and can now progress with pending applications for multiple inhalers and other dosage forms.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has announced that its officials will participate in an investor and analyst meeting on August 19, 2026, at the Motilal Oswal 22nd Annual Global Investor Conference in Mumbai.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd's wholly owned subsidiary, Eugia Pharma Specialities Ltd, received a warning letter from the US FDA for its Unit I formulation manufacturing facility, which has an insignificant impact on the company's overall revenue.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has incorporated a new wholly owned subsidiary company, Auropharm Overseas Limited, to undertake manufacturing and marketing operations in India and foreign countries.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has submitted a notice to the stock exchanges regarding a special window for re-lodging transfer requests of physical shares, and TAAL Tech Limited has announced its unaudited consolidated financial results for the quarter ended June 30, 2026.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has submitted copies of newspaper advertisements of its financial results for the first quarter ended June 30, 2026, as published in Business Standard and Nava Telangana on August 7, 2026.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has announced that its officials will participate in an investor/analyst meet in Singapore and Hong Kong from August 11 to 13, 2026.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has announced the submission of copies of notice published in newspapers for the 39th Annual General Meeting (AGM) to be held on August 27, 2026. The notice was published in Business Standard and Nava Telangana on August 4, 2026, intimating shareholders about the dispatch of the notice of AGM, e-voting information, and book closure dates.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has sent a letter to shareholders who have not registered their email ids, providing a weblink for the integrated Annual Report 2025-26 and informing them about the 39th AGM to be held on August 27, 2026.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, as required by SEBI regulations.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has announced the notice of its 39th Annual General Meeting (AGM) to be held on August 27, 2026, through video conferencing. The AGM will consider and adopt the audited standalone and consolidated financial statements for the financial year ended March 31, 2026, and reappoint two directors, Mr. K. Nithyananda Reddy and Dr. M. Madan Mohan Reddy, who retire by rotation. The AGM will also consider the appointment of a secretarial auditor for a period of 5 years.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd submitted its Integrated Annual Report 2025-26, along with the Notice of 39th Annual General Meeting, to be held on August 27, 2026. The report covers the company's performance, strategic priorities, governance practices, and long-term value creation journey.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has announced that its 39th Annual General Meeting will be held on August 27, 2026, through video conferencing or other audio-visual means.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has scheduled its 39th Annual General Meeting (AGM) to be held on August 27, 2026, through video conferencing. The notice and integrated annual report for the financial year 2025-26 will be sent to shareholders via email and made available on the company's website.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has announced the schedule of an earnings call to be held on August 6, 2026, to discuss the unaudited financial results for the first quarter ended June 30, 2026.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 to consider and approve Intimation of Board Meeting, including the Standalone & Consolidated Unaudited Financial Results of the Company for the first quarter ended June 30, 2026.

Aurobindo Pharma Ltd

Aurobindo Pharma has signed a non-exclusive voluntary license agreement with MSD to supply generic alimatravir to 129 Low- & Middle-Income Countries (LMICs) for HIV prevention, subject to regulatory approvals.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has acquired 80% ownership in A1 Biochem Labs (India) Private Limited and A1 Biochem Labs LLC, USA for an enterprise value of USD 17 million. A1 Biochem Group is a Contract Research Organization (CRO) providing high-quality chemistry services to pharmaceutical companies, biotechs, and academic institutions.

Aurobindo Pharma Ltd

Aurobindo Pharma Ltd has received ANVISA approval for its biosimilars manufacturing facility in Hyderabad, strengthening its capability to supply biosimilar products to the Brazilian and broader Latin American markets.

Aurobindo Pharma Ltd

Aurobindo Pharma USA, a wholly-owned subsidiary of Aurobindo Pharma Ltd, has received U.S. Federal Trade Commission (FTC) approval to acquire Lannett Company LLC for $250 million. This acquisition significantly expands Aurobindo's product offering in complex, non-opioid controlled substances and adds a U.S.-based manufacturing facility. The transaction, expected to close by end of June 2026, is anticipated to be immediately accretive to the Aurobindo Group's earnings per share. It is also projected to generate meaningful cost efficiencies, SG&A synergies, and enhance the company's differentiated pipeline for sustainable long-term growth.